<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Daniel Romdensune Portfolio</title>
    <style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background: #f9f9f9;
        }

        header {
            background: #222;
            color: #fff;
            padding: 20px 0;
        }

        nav {
            margin-top: 10px;
        }

        nav a {
            color: #fff;
            margin: 0 15px;
            text-decoration: none;
            font-weight: bold;
        }

        nav a:hover {
            text-decoration: underline;
        }

        .container {
            max-width: 900px;
            margin: 0 auto;
            padding: 30px 20px;
        }

        .hero {
            background: #4f8cff;
            color: #fff;
            padding: 60px 20px;
            text-align: center;
        }

        .section {
            background: #fff;
            margin: 30px 0;
            padding: 30px 20px;
            border-radius: 8px;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
        }

        h2 {
            color: #4f8cff;
        }

        ul.skills-list {
            list-style: none;
            padding: 0;
        }

        ul.skills-list li {
            background: #e6f0ff;
            margin: 8px 0;
            padding: 10px 15px;
            border-radius: 4px;
            display: inline-block;
            margin-right: 10px;
        }
    </style>
</head>

<body>
    <header>
        <div class="container">
            <h1>Daniel Romdensune (Munson)</h1>
            <div style="margin-top: 10px; color: #b3d1ff; font-size: 1.1em;">
                7434 W. 70th Ave. Arvada, CO. 80003 &nbsp;|&nbsp; Ph – 970-443-2085 &nbsp;|&nbsp; Email – <a
                    href="mailto:djmunson55@gmail.com"
                    style="color:#b3d1ff; text-decoration:underline;">djmunson55@gmail.com</a>
            </div>
            <nav style="margin-top: 15px;">
                <a href="#summary">Summary</a>
                <a href="#experience">Experience</a>
                <a href="#skills">Skills</a>
                <a href="#education">Education</a>
            </nav>
        </div>
    </header>
    <section class="hero" id="summary">
        <h2>Professional Summary</h2>
        <p>A process and product focused scientist with 8 years of industry experience that thrives in a team
            environment where all team members contribute and feel valued in the decision making. Always strives to
            utilize company goals and patient needs to define, develop, and manage programs that drive value for the
            company while delivering life-saving change to patients. Works across the company to ensure that all
            relevant stakeholders are apprised of the progress being made and all deliverables generated.</p>
    </section>
    <div class="container">
        <section class="section" id="experience">
            <h2>Professional Experience</h2>
            <h3>Director – Applications Development<br><span style="font-weight:normal;">Kytopen Corporation – Jan 2024
                    – Sept 2024</span></h3>
            <ul>
                <li>Led a small team of scientists developing marketable applications on Kytopen’s Flowfect platform of
                    instruments which resulted in external facing datasets supporting:
                    <ul>
                        <li>Efficient large volume (up to 1L) editing (pDNA, mRNA, and RNP KO/KI) of model cell lines
                        </li>
                        <li>Robust high concentration (up to 200M cells/mL) editing (pDNA, mRNA, and RNP KO/KI) of model
                            cell lines and primary immune cells</li>
                    </ul>
                </li>
                <li>Headed up the scientific arm of partnership agreements with three clients that were transitioning to
                    Flowfect technology, facilitating the tech transfer of processes and materials from and back to the
                    partner companies:
                    <ul>
                        <li>Partner 1 – TcBuster editing of primary T cells with a CD19 targeting CAR. Achieved &gt;60%
                            CAR+ cells with &gt;90% post transfection viability</li>
                        <li>Partner 2 – TcBuster editing of primary T cells with a BCMA targeting CAR. Achieved &gt;50%
                            CAR+ cells with &gt;85% post transfection viability</li>
                        <li>Partner 3 – mRNA editing of a surrogate macrophage cell line and successful partner editing
                            of primary macrophages following tech transfer. Achieved &gt;70% edit positive cells with
                            &gt;75% post transfection viability</li>
                    </ul>
                </li>
            </ul>
            <h3>Associate Director – Cellular Analytics<br><span style="font-weight:normal;">Artisan Biotechnologies –
                    Aug 2021 – Dec 2023</span></h3>
            <ul>
                <li>Managed a small team developing, qualifying, and implementing assays to support CRISPR editing
                    projects and processes across the company which included:
                    <ul>
                        <li>Image-based cell killing assay used to characterize CAR+ immune cells edited with Artisan’s
                            STAR CRISPR system</li>
                        <li>Three multi-color flow cytometry panels to assess cellular phenotype, edit efficiency, and
                            potency of edited immune and iPS cells</li>
                        <li>Two multi-plex cytokine quantification assays on the MSD platform interrogating
                            functionality and tonic signaling</li>
                        <li>A flow cytometry based assay used to determine GvH and HvG potential following KO and/or KI
                            of cargo to the TCR and/or HLA</li>
                    </ul>
                </li>
                <li>Led the scientific arm of partnership agreements with two potential investing clients looking to
                    license Artisan’s STAR editing technology, generating targeted datasets that supported processes
                    utilized by the clients:
                    <ul>
                        <li>Investor 1 – RNP editing of primary immune cells to KO TCR and HLA I whilst knocking in a
                            CAR to the TCR cut site. Achieved &gt;60% CAR+HLA- edit efficiency with &gt;70% post-edit
                            viability</li>
                        <li>Investor 2 – RNP editing of primary immune cells, knocking in a custom TCR to the native TCR
                            locus with concurrent knockout of the HLA I and II loci. Achieved &gt;50% triple edits while
                            maintaining &gt;70% post-transfection viability</li>
                    </ul>
                </li>
                <li>Developed a LIMS and ELN system in partnership with internal and external Data Management partners
                    supporting all processes within the company. Tested all biological processes within the system prior
                    to release to ensure suitability and led the development of the LIMS inventory management system.
                </li>
            </ul>
            <h3>Senior Scientist – Translational Sciences and Process Development<br><span
                    style="font-weight:normal;">Atara Biotherapeutics – Aug 2016 – Aug 2021</span></h3>
            <ul>
                <li>Led a small team of scientists developing and validating assays to support pharmacokinetic and
                    pharmacodynamic assessments of Atara’s Phase 1 and 2 clinical trial products which included:
                    <ul>
                        <li>Coculture assay to enumerate and assess potency of residual cell therapy product in patient
                            blood as prescribed timepoints after dosing</li>
                        <li>Four ELISA assays looking at markers of CRS in patient serum / plasma to support safety
                            readouts</li>
                    </ul>
                </li>
                <li>Trained and qualified all Quality and Manufacturing staff on the conduct of the above coculture
                    assay for use as a release assay following clinical manufacture of Tabelecleucel in support of
                    Atara’s Phase 3 trials</li>
                <li>Built and managed the clinical sample management and inventory system and performed routine internal
                    audits to ensure regulatory compliance. Acted as the company representative during a regulatory
                    audit of the Translational group during a company wide regulatory audit prior to market
                    authorization of Tabelecleucel</li>
                <li>Managed an external CRO that developed a 56-plex cytokine detection assay interrogating cytokine
                    levels in CSF and serum / plasma from Multiple Sclerosis patients dosed under Atara’s phase 2
                    clinical trial</li>
                <li>As part of the Process Development group, successfully transitioned the static T cell CAR
                    transduction process from GRex vessels to bioreactors with an increase in functional CAR+ cell yield
                    of &gt;200%</li>
            </ul>
        </section>
        <section class="section" id="skills">
            <h2>Skills</h2>
            <ul class="skills-list">
                <li>Expert in molecular biology, immunology, and cell culture</li>
                <li>Expert in assay development, qualification, and validation</li>
                <li>Highly proficient with flow cytometry, cell-based assays, qRT-PCR, ddPCR, and cytokine detection
                    assays</li>
                <li>Proficient with data analysis tools such as FlowJo, GraphPad, and JMP</li>
                <li>Proficient in basic next generation sequencing applications and analyses</li>
                <li>Familiar with advanced next generation sequencing modalities</li>
                <li>Experience validating de novo and routine to complex assays for use on clinical samples in support
                    of regulatory filings</li>
                <li>Experienced with customer facing support, assay development, and technology transfer during
                    collaborative partnerships and CRO-type service work</li>
                <li>Proficient user of the Microsoft (Office, Teams, Sharepoint) and Google (Slack, Confluence, Drive)
                    suites of software</li>
                <li>Comfortable building, testing, and refining a ELN and LIMS systems in support of biological sciences
                    and inventory management</li>
                <li>Experienced with task management software (MS Project, Wrike) to ensure timeline adherence and
                    tracking</li>
                <li>Successful track record managing teams within a collaborative, cross-functional environment</li>
            </ul>
        </section>
        <section class="section" id="education">
            <h2>Education</h2>
            <ul>
                <li><strong>Post-Doctoral Research</strong> – University of Colorado 2012 – 2016<br>
                    <span style="font-weight:normal;">Identification of the TCR repertoires of tumor resident T cells
                        shared across HLA-related breast cancer patients</span>
                </li>
                <li><strong>Doctorate in Biomedical Sciences</strong> – SUNY at Albany 2006 – 2011<br>
                    <span style="font-weight:normal;">Discovery and characterization of microRNAs produced by
                        HSV-1</span>
                </li>
                <li><strong>Bachelor of Science in Microbiology</strong> – Colorado State University 1998 – 2002</li>
            </ul>
        </section>
    </div>
</body>

</html>
